Testing a Weekly Weight‑Loss Drug in Chinese Adults

The study followed Chinese adults for 76 weeks. It was a multi‑site, randomized, double‑blind trial. Participants received either a weekly injection of survodutide (3.6 mg or 4.8 mg), a placebo, or both plus lifestyle advice. The trial aimed to see if the drug could help people lose weight safely.

To join, people needed a BMI of at least 28, or a BMI of 24 or higher plus another health issue linked to excess weight. The groups were split evenly: one‑third got the lower dose, one‑third got the higher dose, and one‑third got the dummy treatment. Everyone also took part in a lifestyle program.

At the start, 306 volunteers took part. Their average age was about 37. They weighed around 94 kg and had a waist of roughly 106 cm. The average BMI was 33.2 and triglycerides were 2.2 mmol/L. Nearly half were women. About 73 % already had a related health problem such as fatty liver disease, high cholesterol, high blood pressure, or type 2 diabetes. Some also had sleep apnea or heart issues. Around one‑fifth showed signs of pre‑diabetes.

The main goals were to measure how much weight participants lost and whether they reached a 5 % reduction after a year. Researchers also watched for any side effects. The trial was designed to give a clear picture of survodutide's effectiveness and safety for treating overweight and obesity in this population.